Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
Date:11/8/2010

accelerated the rate of viral clearance, with comparable response at ANA598 doses of 200 mg bid and 400 mg bid.  ANA598 also showed an excellent safety profile in the study through the 12 weeks of dosing, with reported adverse events being typical for patients treated with interferon and ribavirin alone, although conclusions regarding safety cannot be made until results in more patients over longer duration are known.  Slides from the oral presentation are available on the Company's website at www.anadyspharma.com.On November 2, 2010, additional data from the ongoing Phase IIa trial were presented at AASLD showing that the addition of ANA598 to SOC conferred benefit in both the patients with the IL-28B genotypes most and less responsive to SOC in a poster titled, "IL28B Polymorphism and Kinetics of Antiviral Activity for ANA598 in Combination with Pegylated Interferon alpha 2A Plus Ribavirin in Treatment-Naïve Genotype-1 Chronic HCV Patients."  The poster is available on the Company's website at www.anadyspharma.com.


  • Phase IIa Study of ANA773 in HCV.  In October, Anadys announced that it plans to resume clinical investigation of ANA773 in hepatitis C patients.  ANA773 is an oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway.  The Company intends to conduct a 28-day study of ANA773, in combination with ribavirin in the first cohorts and as triple therapy in combination with ribavirin and a direct-acting antiviral (DAA) in subsequent cohorts. Anadys intends to conduct this study in Europe and potentially other countries, and expects that up to approximately 75 patients will participate in the trial, inclusive of the DAA cohorts.Recent Operational Highlights

  • Closed Underwritten Public Offering of Common Stock.  In October, Anadys closed an underwritten public offering through the sale of c
    '/>"/>


  • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
    3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
    4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
    5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
    6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
    7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
    8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
    9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
    10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
    11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... 2014 The Brandeis Medical Center, led by Dr. Emmanuel ... and affordable laser tattoo removal experience with the advanced Astanza Duality ... providing high quality cosmetic services with cutting edge medical technology and ... Southern California has seen a dramatic increase in the ...
    (Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
    (Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
    Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
    ... Sevocity, a division of Conceptual MindWorks, Inc. (CMI), today ... as a preferred electronic health record (EHR) vendor with ... leading true Internet or cloud-based EHR. This enables Sevocity ... health record system with low start-up cost and affordable ...
    ... STAMFORD, Conn., July 20, 2011 A new online ... healthcare professionals, law enforcement, and community organizations combat the ... Purdue Pharma L.P . has developed RxSafetyMatters.org ... company and organizations with which it is partnering to ...
    Cached Medicine Technology:Sevocity® Named Preferred EHR Vendor by CITIA-SC, South Carolina's Health IT Regional Extension Center (REC) 2New Online Resource to Help Combat Abuse of Prescription Medications Launched by Purdue Pharma L.P. 2New Online Resource to Help Combat Abuse of Prescription Medications Launched by Purdue Pharma L.P. 3
    (Date:4/22/2014)... ARBOR, Mich. Nearly 7 in 10 Americans ... a new national survey by researchers at the University ... with children under the age of 18 at home, ... more likely than other adults to support universal coverage ... appear in the Journal of the American Medical ...
    (Date:4/22/2014)... patients diagnosed with non-small cell lung cancer are 70 ... percentage, these elderly patients are not well represented in ... made it difficult to reach evidence based clinical recommendations. ... Task Force and Lung Cancer Group along with the ... opinion on managing treatment for elderly patients with non-small ...
    (Date:4/22/2014)... parallel with modern man ( Homo sapiens ), there were ... side by side, such as Neanderthals and the recently discovered ... survived. What was it in our genetic makeup that gave ... known about our unique genetic makeup as distinguished from our ... we are the only species among them ,to survive. Even ...
    (Date:4/22/2014)... DC -- When mothers are exposed to trauma, illness, ... a single molecular trigger in brain cells that can ... stress disorder and some forms of autism. , Until ... have impacted the cells of a developing brain. Past ... herself to alcohol or drug abuse or she experiences ...
    (Date:4/22/2014)... may be influenced by low exposure to testosterone in ... revealed how men,s testosterone levels may be determined before ... less of the hormone than others is important because ... of the hormone have been linked to obesity, diabetes ... cells responsible for producing testosterone in adults known ...
    Breaking Medicine News(10 mins):Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:What gave us the advantage over extinct types of humans? 2Health News:Life stressors trigger neurological disorders, researchers find 2
    ... designed to treat chronic inflammatory conditions and leukemia resulted ... men involved in the trail becoming seriously ill. ... drug reaction. ,Dr. Ganesh Suntharalingam and colleagues ... immune system overreaction, known as a cytokine storm, was ...
    ... Clinton and Microsoft boss Bill Gates said inadequate access to ... combating the AIDS epidemic, in addresses to the largest ever ... continue to fight the stigma and stop people from being ... ,Both Clinton and Gates have donated billions of dollars ...
    ... be programmed to encourage fidgeting and other restless behaviors that ... research published by The American Physiological Society. ,The ... lean are more sensitive to a chemical produced in the ... such as fidgeting and other unconscious movements. Compared to rats ...
    ... good alternative for identifying risks for kidney disease, cardiovascular disease, ... a researcher at the San Francisco VA Medical Center, has ... incapable of picking up chronic health risks among the elderly., ... at risk for kidney disease, this is an important message: ...
    ... Neurosciences Institute in Rockville have claimed that the discovery ... patients// with Alzheimer's disease, could be developed as a ... ,The researchers explained that not only would be quick ... test for diagnosing Alzheimer's disease, which as of now ...
    ... Eighth International Conference on Mercury as a Global Pollutant, ... noted that Mercury pollution// can threaten the health of ... remote corners of the planet, but reducing mercury use ... declaration essentially says that mercury pollution is a problem ...
    Cached Medicine News:Health News:Experimental Drug Causes Cytokine Storm 2Health News:Biological Basis Behind a Couch Potato 2Health News:Biological Basis Behind a Couch Potato 3Health News:Cystatin C Test- A Reliable Test to Detect Chronic Health Risks 2Health News:Cystatin C Test- A Reliable Test to Detect Chronic Health Risks 3Health News:Scientists Claim Developing A New Skin Test For The Early Detection Of Alzheimer’ 2Health News:Dangers Of Mercury 2
    ... System is designed to help physicians provide ... leg. Endovenous laser therapy is a patient-friendly ... of varicose veins., In endovenous laser therapy, ... the varicosed vein, generally through a small ...
    ELVeS is a new minimally-invasive laser treatment for patients with superficial vein reflux of the greater saphenous vein. The ELVeS laser treatment offers your patients an effective out-patient alt...
    Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
    ... #1 physician choice in laser treatment, brings ... superficial vein reflux. EVLT is a minimally ... stripping that effectively and safely treats varicose ... occlude the vein. The procedure is easy ...
    Medicine Products: